Literature DB >> 3275554

Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment.

B Kuglin1, F A Gries, H Kolb.   

Abstract

IgG proinsulin autoantibodies (IgG-PAAs) have been found in a fraction of sera from patients with newly diagnosed insulin-dependent diabetes mellitus (IDDM) before onset of insulin treatment. Only sera lacking insulin antibodies have been analyzed, to avoid interference. Competitive inhibition studies provide specificity for human proinsulin but not for insulin. IgG-PAAs largely cross-react with human C-peptide. Precursors of insulin thus are involved in the immune process of IDDM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275554     DOI: 10.2337/diab.37.1.130

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  14 in total

1.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

Review 2.  Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.

Authors:  Zhuo Fu; Elizabeth R Gilbert; Dongmin Liu
Journal:  Curr Diabetes Rev       Date:  2013-01-01

3.  Clonally restricted insulin autoantibodies in a cohort of 2200 healthy blood donors.

Authors:  J C Sodoyez; F Sodoyez-Goffaux; M Koch; D Sondag; C Bouillenne; C François-Gérard; E Bosi
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

4.  Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.

Authors:  Peter Achenbach; Kerstin Koczwara; Annette Knopff; Heike Naserke; Anette-G Ziegler; Ezio Bonifacio
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies.

Authors:  K Böhmer; H Keilacker; B Kuglin; A Hübinger; J Bertrams; F A Gries; H Kolb
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

6.  Insulin autoantibodies as determined by competitive radiobinding assay are positively correlated with impaired beta-cell function--the Ulm-Frankfurt Population Study.

Authors:  N Yassin; J Seissler; M Glück; B O Boehm; E Heinze; E F Pfeiffer; W A Scherbaum
Journal:  Klin Wochenschr       Date:  1991-10-18

7.  Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes.

Authors:  G Rudy; N Stone; L C Harrison; P G Colman; P McNair; V Brusic; M B French; M C Honeyman; B Tait; A M Lew
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

8.  Detection of autoantibodies against islet amyloid polypeptide in human serum. Lack of association with type 1 (insulin-dependent) diabetes mellitus, or with conditions favouring amyloid deposition in islets. The Belgian Diabetes Registry.

Authors:  F K Gorus; J C Sodoyez; D G Pipeleers; B Keymeulen; A Foriers; C F Van Schravendijk
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

9.  Influence of affinity of antibodies upon their detection by liquid phase radiobinding assay and solid phase enzyme linked immunosorbent assay. Demonstration using monoclonal antibodies raised against rDNA human proinsulin.

Authors:  J C Sodoyez; M Koch; I Lemaire; F Sodoyez-Goffaux; A Rapaille; C François-Gérard; D Sondag
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

10.  Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice.

Authors:  Karine Thébault-Baumont; Danielle Dubois-Laforgue; Patricia Krief; Jean-Paul Briand; Philippe Halbout; Karine Vallon-Geoffroy; Joëlle Morin; Véronique Laloux; Agnès Lehuen; Jean-Claude Carel; Jacques Jami; Sylviane Muller; Christian Boitard
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.